The effectiveness of the integrated use of gepadif, ezetrol and fosinopril in the nonalcoholic steatohepatitis in patients with hypertension stage II
DOI:
https://doi.org/10.14739/2310-1210.2013.5.18937Keywords:
nonalcoholic steatohepatitis, metabolic syndrome, hypertensionAbstract
There are the data on the features of the treatment of patients with nonalcoholic steatohepatitis on the background of the 2nd stage of hypertension and metabolic syndrome are given in the article. Comparative characteristic of dynamic quality indexes of the treatment with the traditional medicines and with the use of Gepadif, Ezetrol and Fosinopril was done.
References
Буеверов А.О. Неалкогольная жировая болезнь печени: обоснование патогенетической терапии / А.О. Буеверов, П.О. Богомолов // Клинические перспективы в гастроэнтерологии, гепатологии. – 2009. – №1. – С. 3–9.
Губергриц Н.Б. Эффективность гепадифа в лечении неалкогольного стеатогепатита, развившегося вследствие абдоминального ишемического синдрома / Н.Б. Губергриц, Е.Ю. Голуб // Клін. та експеримент. патологія. – 2008. – Т. 7, №3. – С. 142–146.
Клініко-фармакологічні властивості та особливості застосування комбінованого гепатопротекторного препарату «Гепадиф» як препарату терапії супроводу при прийомі статинів / І.С. Чекман, Н.В. Харченко, Г.А. Анохіна [та ін.] // Сучасна гастроентерол. – 2010. – №4. – С. 77–81.
Соколова Н.А. Исследование антиатерогенной эффективности статинов и комбинации статина cингибитора мадсорбции холестерина эзетимибом у больных с каротидным атеросклерозом: автореф. дис. … канд. мед. наук по спец.: 14.03.06 – фармакология, клиническая фармакология, 14.01.05 – кардіология / Н.А. Соколова. – М., 2010. – 28 с.
Georgescu E.F. Angiotensin receptor blockers in the treatmentof NASH/NAFLD: couldtheybe a fi rst-classoption? / E.F. Georgescu // Adv. Ther. – 2008. – Vol. 25, №11. – P. 1141–1174.
Lam B.Treatmentoptionsfornonalcoholicfattyliverdisease / B. Lam, Z.M. Younossi // Therap. Adv. Gastroenterol. – 2010. – Vol. 3, №2. – P. 121–137.
Managing nonalcoholicfatty liver disease: recommendations for family physicians / I. Grattagliano, P. Portincasa, V.O. Palmieri [etal.] // Can.Fam. Physician. – 2007. – Vol. 53, №5. – P. 857–863.
Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study / M. Ekstedt, L.E. Franzén, U.L. Mathiesen [etal.] //J. Hepatol. – 2007. – Vol. 47, №1. – P. 135–141.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
